Advertisement
Advertisement
FBLG
FibroBiologics, Inc. Common Stock
0.98
USDSponsored
+0.02
+2.39%
Nov 06, 15:59 UTC -5
Closed
Pre-Market
1.00
+0.02
+2.39%
FibroBiologics, Inc. Common Stock (FBLG) Earnings
FBLG Earnings Reports
Positive Surprise Ratio
FBLG beat 5 of 9 last estimates.
56%
Next Report
Today
Date of Next Report
Nov 09, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/-$0.64
Implied change from Q2 26 (Revenue/ EPS)
--
/-3.03%
Implied change from Q3 25 (Revenue/ EPS)
--
/-75.38%
FibroBiologics, Inc. Common Stock earnings per share and revenue
On Jul 31, 2026, FBLG reported earnings of -0.66 USD per share (EPS) for Q2 26, beating the estimate of -0.73 USD, resulting in a 10.13% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +12.93% price change (close before vs. close after earnings).
Looking ahead to Q3 26, -- analysts forecast an EPS of -0.64 USD, with revenue projected to reach -- USD, implying an decrease of -3.03% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Aligos Therapeutics, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$2.21
Actual
-$2.09
Surprise
+5.58%
CervoMed Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.49
Actual
-$0.39
Surprise
+21.97%
Creative Medical Technology Holdings, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.24
Actual
-$0.40
Surprise
-63.40%
Medicus Pharma Ltd. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$6.75
Actual
-$11.64
Surprise
-72.25%
Moderna, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$1.27
Actual
$0.38
Surprise
+129.79%
Bio-Techne Corp.
Report Date
Nov 06, 2026 For Q1 27
Estimate
$0.44
Actual
$0.44
Surprise
-1.96%
Immunocore Holdings plc - ADR
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.13
Actual
-$0.28
Surprise
-104.08%
Entera Bio Ltd. Ordinary Shares
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.06
Actual
-$0.11
Surprise
-58.50%
Vogenx Inc Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.47
Surprise
-187.99%
Agenus Inc.
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.27
Actual
$0.02
Surprise
+107.26%
FAQ
What were FibroBiologics, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, FibroBiologics, Inc. Common Stock reported EPS of -$0.66, beating estimates by 10.13%, and revenue of $0.00, 0% as expectations.
How did the market react to FibroBiologics, Inc. Common Stock's Q2 2026 earnings?
The stock price moved up 12.93%, changed from $0.70 before the earnings release to $0.79 the day after.
When is FibroBiologics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 09, 2026.
What are the forecasts for FibroBiologics, Inc. Common Stock's next earnings report?
Based on --
analysts, FibroBiologics, Inc. Common Stock is expected to report EPS of -$0.64 and revenue of -- for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.